The Master in Sciences, in the specialty of Fermentation, Jesús Zamora Sánchez, director of the institution, showed to Adelante newspaper that the development of the science is constant, a valued virtue, undoubtedly, in this group.

They wraped up 2014 with great outcomes in the Phase 2 of the Heber Provac, vaccine candidate against the cancer of prostate, qualified by the director as promissory and with the perspective of kicked off in 2015 the Phase 2-3, with 300 patients in different clinical places of the country.

Also the Gavac, vaccine against the tick of the bovine cattle, continues its exponential growth on the foreign market and that in 2016 should duplicate its level.

A pity that the same cannot be said towards the internal market. The stockbreeders or those who direct them have not taken seriously its use and with the high effectiveness that shows, in moments in which the mass needs to be reproduced.

The center also develops a new vaccine that will substitute Gavac. It is not yet registered and must go out to the market in a term of two to three years with effectiveness superior to the current one.

Along with the center of Havana it is foreseen the product appear on the market in 2016 against the classic porcine fever, technology of production to be established in 2015.

The institution, conceived to investigate in its origins, jumped towards the technologies development, obtained products and commercializes them with what closes the finished cycle, antechamber of the export.

The Heber Nem, of local creation like nematicide to control phitonematodes, plants parasites, in the current year is projected to transfers its technology to Euroasia.

Translated by BA in English Language, Manuel Barrera Téllez

{flike} {plusone} {ttweet}